1,515
Views
21
CrossRef citations to date
0
Altmetric
Systematic Review

Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials

, , , , , , , ORCID Icon & show all
Pages 63-74 | Received 22 Dec 2020, Accepted 01 Mar 2021, Published online: 12 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Nicole Ledwos, Aurelia I. Andreiev, Tianna Costa, Nitin Chopra & Tony P. George. (2023) Successful treatment of dextromethorphan use disorder with combined naltrexone and gabapentin: a case report. The American Journal of Drug and Alcohol Abuse 49:2, pages 266-267.
Read now
Bartłomiej Pochwat, Anna Julia Krupa, Marcin Siwek & Bernadeta Szewczyk. (2022) New investigational agents for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs 31:10, pages 1053-1066.
Read now

Articles from other publishers (18)

Mu-Hong Chen & Shih-Jen Tsai. (2023) Maintenance of antidepressant effect by dextromethorphan in patients with treatment-resistant depression who respond to ketamine intervention. Medical Hypotheses, pages 111242.
Crossref
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, Alessandro Serretti & Chiara Fabbri. (2023) Clinical specificity profile for novel rapid acting antidepressant drugs. International Clinical Psychopharmacology 38:5, pages 297-328.
Crossref
Alessandro Serretti. (2023) Anhedonia and Depressive Disorders. Clinical Psychopharmacology and Neuroscience 21:3, pages 401-409.
Crossref
Aileen M. Bailey, Allison Barrett, Lane Havens, Erica Leyder, Taylor Merchant, Hannah Starnes & Scott M. Thompson. (2023) Changes in social, sexual, and hedonic behaviors in rats in response to stress and restoration by a negative allosteric modulator of α5-subunit containing GABA receptor. Behavioural Brain Research 452, pages 114554.
Crossref
Itamar Shapira, Bradley G. Burk, Harrison Hill & Brandon S. Pruett. (2023) Playing with a full dex of cards: Treatment resistant depression with suicidality responds to inpatient dextromethorphan therapy. Psychiatry Research Case Reports 2:1, pages 100105.
Crossref
Mujeeb U. Shad. (2023) Recent Developments in Pharmacotherapy of Depression: Bench to Bedside. Journal of Personalized Medicine 13:5, pages 773.
Crossref
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, Jessica R. Gilbert, Ioline D. Henter & Carlos A. ZarateJr.Jr.. (2023) Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 226, pages 109422.
Crossref
Shiyun Lv, Kejie Yao, Youyi Zhang & Shujia Zhu. (2023) NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. Neuropharmacology 225, pages 109378.
Crossref
Bruno Pedraz‐Petrozzi, Michael Deuschle & Maria Gilles. (2023) Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment‐resistant depression and psychiatric comorbidities. Clinical Case Reports 11:3.
Crossref
Yian Chen, Eric Wang, Brian D Sites & Steven P Cohen. (2023) Integrating mechanistic-based and classification-based concepts into perioperative pain management: an educational guide for acute pain physicians. Regional Anesthesia & Pain Medicine, pages rapm-2022-104203.
Crossref
Golnoush Banaei-Boroujeni, Ameneh Rezayof, Sakineh Alijanpour & Farzaneh Nazari-Serenjeh. (2023) Targeting mediodorsal thalamic CB1 receptors to inhibit dextromethorphan-induced anxiety/exploratory-related behaviors in rats: The post-weaning effect of exercise and enriched environment on adulthood anxiety. Journal of Psychiatric Research 157, pages 212-222.
Crossref
Steven Marwaha, Edward Palmer, Trisha Suppes, Emily Cons, Allan H Young & Rachel Upthegrove. (2023) Novel and emerging treatments for major depression. The Lancet 401:10371, pages 141-153.
Crossref
Karan Kverno. (2022) Dextromethorphan: From Cough Suppressant to Antidepressant. Journal of Psychosocial Nursing and Mental Health Services 60:11, pages 9-11.
Crossref
R. Guglielmo & G. Hasler. (2022) The neuroprotective and neuroplastic potential of glutamatergic therapeutic drugs in bipolar disorder. Neuroscience & Biobehavioral Reviews 142, pages 104906.
Crossref
Yu-Ming Wang, Cong-Yuan Xia, Hong-Mei Jia, Jun He, Wen-Wen Lian, Yu Yan, Wen-Ping Wang, Wei-Ku Zhang & Jie-Kun Xu. (2022) Sigma-1 receptor: A potential target for the development of antidepressants. Neurochemistry International 159, pages 105390.
Crossref
Octavian Vasiliu. (2022) Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents. Frontiers in Pharmacology 13.
Crossref
M. A. Novitsky, A. De Sousa, A. R. Asadullin, O. A. Gavrilyuk, A. V. Petrov & R. F. Nasyrova. (2021) Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia. Personalized Psychiatry and Neurology 1:2, pages 21-45.
Crossref
Joshua D. Di Vincenzo, Orly Lipsitz, Nelson B. Rodrigues, Yena Lee, Hartej Gill, Kevin Kratiuk, Mehala Subramaniapillai, Rodrigo Mansur, Roger S. McIntyre & Joshua D. Rosenblat. (2021) Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. Journal of Psychiatric Research 143, pages 209-214.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.